bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C141: From insights to action: Engaging women living with HIV in the data-driven development of an mHealth intervention for cervical cancer prevention and HPV self-sampling
Authors: Le Daisy , Ciceron Annie Coriolan , Jeon Min (Jaime) Jeong , Abroms Lorien C. , Berg Carla J. 
Published: December 2023

Abstract
Background: Women living with HIV (WLH) face a higher risk of invasive cervical cancer (CC) due to a greater incidence and longer persistence of high-risk human papillomavirus (HPV) infection. Health education programs, including text-messaging interventions, have demonstrated effectiveness in improving CC and HPV knowledge and promoting recommended screening. Emerging strategies involving self-collected cervicovaginal samples as an alternative to office-based HPV screening offer additional promise in reaching women who face several obstacles to timely care, such as WLH. Purpose: This mixed-methods study aims to describe the data-driven development of a four-week text-messaging intervention, named “My Self-Sampling, HPV Awareness, Results, and Empowerment (MySHARE)”, to improve CC prevention knowledge and promote HPV self-sampling among WLH. Methods: Surveys (n=81) and focus group discussions (FGDs; n=39) were conducted among WLH in the Washington-Baltimore metropolitan region, with the findings guiding the development of MySHARE. Results: While most WLH indicated that in-person group sessions were their typical source of health information, they highlighted the impracticality of these sessions since the pandemic and expressed openness to a text-messaging intervention. Survey results informed the logistical aspects and functionality of the intervention, while FGD participants' responses, guided by constructs from the Protection Motivation Theory, shaped the content of the text-messaging library. The library covered topics such as CC and HPV knowledge, prevention behaviors, and HPV self-sampling. Conclusions: This study emphasizes the significance of engaging the target population in intervention development. WLH participants provided clear and actionable recommendations, which, together with best practices in digital health technology, directed decisions on the intervention delivery platform, messaging timing and frequency, and text-messaging content. Low-cost and accessible interventions like MySHARE have the potential to substantially enhance CC and HPV knowledge, as well as screening rates, among historically underserved populations, particularly during public health crises.
Citation Format: Daisy Le, Annie Coriolan Ciceron, Min (Jaime) Jeong Jeon, Lorien C. Abroms, Carla J. Berg. From insights to action: Engaging women living with HIV in the data-driven development of an mHealth intervention for cervical cancer prevention and HPV self-sampling [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C141.
Abstract IA010: American Indian community engagement in culturally respectful cancer interventions
Authors: Burhansstipanov Linda 
Published: December 2023

Abstract
This 10-minute session begins with a brief overview of strengths within American Indian communities. Cultural perceptions of research are summarized followed by a list of unsuccessful recruitment strategies. Missed opportunities for the inclusion of sufficient numbers of American Indians in national clinical trials will be reviewed. An overview of American Indians’ desire for inclusion in respectful clinical trials research will include an excerpt from Clinical Trials for Native Americans: A Gift for our Children. Healthcare Providers impact on inclusion of underserved populations will be summarized followed by a synopsis based on involvement of competency trained Native Patient Navigators to assist with CT recruitment. Some annoyances practiced by research institutions that negatively impact involvement of American Indian communities will be shared followed by recommendations for increasing engagements. The segment will close with a summary of significant gaps in American Indian cancer research programs.
Citation Format: Linda Burhansstipanov. American Indian community engagement in culturally respectful cancer interventions [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA010.
Abstract IA031: Equitable access to clinical trials: The role of community healthcare systems
Authors: Osarogiagbon Ray U. 
Published: December 2023

Abstract
Approximately 85% of US cancer care is delivered in community healthcare systems, most of which have no formal affiliation with academic programs and do not identify the research mission as a core responsibility. Therefore, most community-based cancer programs are research deserts. Yet there is strong evidence to support the oft-cited statement: 'the best treatment is a clinical trial.' In this age of rapid-fire discovery and clinical trials driven by deep knowledge of cancer biology and drug chemistry, coupled with close regulatory oversight, clinical trials carry much smaller risk for participants than ever before. In the end, clinical trials provide access to tomorrow's treatment, today. The socio-ecological model of healthcare recognizes that most problems and solutions reside at the levels of the individual, clinician, organization and social policy. As the number of actors sequentially diminishes from the individual to the social policy levels, the potential enduring impact of interventions sequentially rises. Interventions directly targeting the individual level are least efficient, those that target key social policies have the greatest enduring impact. So with the wicked challenge of inequitable clinical trials access. We will focus on the institutional level in my solutions-oriented discussion of equitable access to clinical trials. Using the NCI's Minority-Underserved NCORP progam and the Baptist Memorial Health Care Corporation as living examples, we will review intervention frameworks, objectively analyze the barriers to clinical trials access, and provide a pragmatic discussion of stakeholder-centered approaches to building clincial trials infrastructure in the places where people routinely seek care. We propose approaches to integrate clincal research as a core component of cancer care delivery in community healthcare systems and make the case that key external stakeholders, including patient advocacy groups, sponsors of research and healthcare policymakers must meet the target population where they reside. That connection can only happen by building clinical trials infrastructure and manpower within community healthcare systems.
Citation Format: Ray U. Osarogiagbon. Equitable access to clinical trials: The role of community healthcare systems [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA031.
Abstract IA045: Hepatitis C virus (HCV) screening and treatment in South Texas US-Mexico border persistent poverty counties
Authors: Flores Bertha E. , Guerrero Juan , Bobadilla Raudel , Craven Catherine K. 
Published: December 2023

Abstract
Background: Hepatitis C Virus (HCV) is a major risk factor for Hepatocellular carcinoma (HCC), early screening of HCV is essential for the prevention of HCC. Other risk factors for cancer are those associated with poverty including low socioeconomic status and lack of access to health care. These risk factors are prominent among hispanic populations who have higher rates of liver cancer. In 2021, Hispanic liver cancer (incidence and mortality) was almost doubled as compared to non-Hispanic whtes. In Texas, the incidence of liver cancer is higher for Hispanics and particularly for those living in South Texas. Methods: We implemented an multi-component intervention (STOP-HCC-HCV) to increase access to HCV screening and treatment in two clinic systems predominantly serving low-income Hispanic ommunities in three South Texas persistent poverty counties. We used a Hybrid type 1 implementation effectiveness study design to evaluate the program's impact using both qualitative and quantitative data. Results: Using the RE-AIM framework, we increased HCV screening rates from 10% in 2021, to 78% in 2023 among adults 18-56 years of age. We successfully naviagted uninsured patients to treatment and cure and have 100% success rate for ordering Direct Acting Antivirals. Conclusion: Using a multi-component intervention, and decreasing barriers to healthcare increased HCV screening and treatment to ultimetly decrease cancer health disparities among vulnerable populations living in persistent poverty counties.
Citation Format: Bertha E. Flores, Juan Guerrero, Raudel Bobadilla, Catherine K. Craven. Hepatitis C virus (HCV) screening and treatment in South Texas US-Mexico border persistent poverty counties [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr IA045.
Treatment of Cervical Precancers is the Major Remaining Challenge in Cervical Screening Research
Authors: Desai Kanan T. , de Sanjosé Silvia , Schiffman Mark 
Published: December 2023

AbstractDeepening understanding of cervical cancer pathogenesis has yielded one-dose prophylactic human papillomavirus (HPV) vaccines and accurate HPV-based cervical screening tests. Knowing the heterogeneous carcinogenic potential of the individual high-risk HPV types permits prioritization of vaccination and screening strategies. However, “correct” (i.e., safe and effective) treatment of women found to have precancer is still undefined, forcing reliance on one or more rounds of untargeted destructive/excisional treatment. Both over-treatment and under-treatment are common results. Until safe and effective anti-HPV therapies are invented, defining optimal destructive/excisional treatment of precancer remains a fundamental and under-researched challenge, especially in resource-constrained settings.See related article by King et al., p. 681
Abstract A017: Exploring the interplay between macrophage subtypes and colorectal cancer cell growth
Authors: Chiang Chun-Te , Hixon Danielle , Mooradian Nevart , Kshetri Pratiksha , Valena Scott , Lau Roy , Ambrose Charlie , Doche Michael , Hill Reginald , Mumenthaler Shannon M. 
Published: December 2023

Abstract
Tumor-associated macrophages, a major stromal component within the tumor microenvironment (TME), play diverse roles in tumor progression and response to therapy. Although their tumor infiltration is linked to unfavorable prognoses in various cancer types, their specific involvement in colorectal cancer (CRC) remains a subject of debate. Within the TME, macrophages can adopt pro-inflammatory (M1) or immune-suppressive (M2) phenotypes in response to signals. In this study, we aimed to investigate the intricate interplay between CRC cells and macrophages under different tumor microenvironmental stresses, shedding light on the impact of macrophage phenotype and function on tumor cell behavior. We characterized signaling pathways and macrophage markers in the THP-1 monocytic cell line, differentiating THP-1 cells into M0 macrophages and polarizing them into M1 and M2 phenotypes using distinct inducers, LPS+IFNγ or IL4+IL13, respectively. Treatment with M1 and M2 inducers resulted in the induction of p-STAT1 and p-STAT6 signaling, as well as metabolic markers like IDO and TGM2, respectively, in THP-1 cells. Subsequently, we collected conditioned media (CM) from M0, M1, and M2 macrophages and assessed their impact on colon cancer cell proliferation. Consistent with previous studies, M1 CM demonstrated a suppressive effect on the growth of several CRC cell lines, whereas M0 or M2 CM did not elicit a change. Interestingly, we found a few CRC lines where the M1 CM did not reduce cell growth, suggesting that the response to M1 macrophages may be influenced by tumor cell-intrinsic factors. To gain further insights, a high-content imaging-based workflow was utilized for physical co-cultures of macrophage subtypes and CRC cells. Furthermore, we validated our findings using patient-derived tumor organoids to examine the interaction between macrophages and CRC in a more physiologically relevant context. Overall, our systematic exploration provides valuable insights into the complex interplay between macrophage subtypes and the progression of colon cancer. It emphasizes the influence of the tumor immune microenvironment on cancer cell behavior across diverse intrinsic cellular factors.
Citation Format: Chun-Te Chiang, Danielle Hixon, Nevart Mooradian, Pratiksha Kshetri, Scott Valena, Roy Lau, Charlie Ambrose, Michael Doche, Reginald Hill, Shannon M. Mumenthaler. Exploring the interplay between macrophage subtypes and colorectal cancer cell growth [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A017.
Abstract A023: Nicotinamide Phosphoribosyltransferase (NAMPT) is required for trained macrophage-mediated antitumor immunity
Authors: Jin Huan , Liu Yongxiang , Xia Xiaojun 
Published: December 2023

Abstract
Trained immunity or innate immune memory plays an active role in suppressing tumour growth and metastasis, however the specific metabolic mechanisms underlying such memory response-mediated antitumor activity have not been fully elucidated. Here, we show that the Nicotinamide Phosphoribosyltransferase/Nicotinamide Adenine Dinucleotide (NAMPT/NAD+) axis is required for the establishment of immune memory in macrophages against tumour. Chemical inhibition or genetic knockout of NAMPT in macrophages blocked trained immunity in vitro and in vivo, which could be rescued by NMN, an NAD+ precursor and a direct metabolite of NAMPT. Further studies revealed that myeloid-specific knockout of Nampt in mice significantly impaired the antitumor effect induced by in vivo β-glucan training, accompanied with decreased infiltration of intratumoral M1 macrophages. Interestingly, NAMPT deficiency did not impair β-glucan-induced interferon signalling or Akt/mTOR/HIF-1α signalling pathway, but markedly reduced histone methylation and acetylation levels, suggesting that NAMPT/NAD+ axis regulates trained immunity in macrophages via potential epigenetic mechanisms. Collectively, our study identifies that NAMPT/NAD+ metabolic axis-regulated trained immunity is a critical mechanism in early immune surveillance that suppresses tumour development via epigenetic regulation.
Citation Format: Huan Jin, Yongxiang Liu, Xiaojun Xia. Nicotinamide Phosphoribosyltransferase (NAMPT) is required for trained macrophage-mediated antitumor immunity [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A023.
Abstract A029: Treatment-Specific Immune Phenotypes Identified by nELISA High-Throughput Proteomics Reveal Actionable Insights for Drug Discovery
Authors: Robichaud Nathaniel , Ongo Grant , Teahulos Ivan , Rho Woojong , Dagher Milad 
Published: December 2023

Abstract
Understanding tumor immunology requires high content tools that can capture the complex microenvironment, as well as high-throughput cell-based assays to rapidly screen compounds, antibodies, or cell therapies. Unfortunately, proteomics tools to investigate interactions between cancer and immune cells compromise either content or cost, limiting access to phenotypic data. To overcome this issue, we developed the nELISA: a high-throughput miniaturized ELISA quantifying 191 cytokines, chemokines, proteases and growth factors, at 10x-reduced cost compared to previous tools, and applied it to cell based models to demonstrate its ability to characterize immune phenotypes in co-culture systems. We ran the largest PBMC secretome screen to date, in which ~10,000 PBMC samples were treated with various inflammatory stimuli, and were further perturbed with a selected library of 80 recombinant protein “perturbagens”. 191 secreted proteins were profiled in all samples, resulting in ~2M datapoints. The nELISA profiles were able to capture phenotypes associated with specific stimulation conditions, individual donors, and potent cytokine perturbagens. By compensating for stimulation and donor differences, we clustered perturbagens according to their effects on PBMC secretomes. As expected, perturbagens such as IFN gamma and IL-4 led to well-established Th1 or Th2 responses, respectively, and clustered with perturbagens involved in these phenotypes. Novel phenotypic effects were also identified, such as distinct responses to the near identical CXCL12 alpha and beta isoforms. Interestingly, we observed important similarities between PBMC responses to the cytokine drugs IFN beta and IL-1 Receptor antagonist, supporting the use of the latter as a replacement for the former in certain indications. These findings highlight the ability of the nELISA to capture actionable insights from high-throughput screens, and demonstrate its applicability to SAR studies and drug repurposing screens. Thus, the nELISA is a powerful tool for immunotherapy drug discovery, and we will expand upon its use for target identification, in vitro pharmacology, predicting patient response to therapy, as well as characterizing the potential of iPSC- or donor-derived material for cell therapy.
Citation Format: Nathaniel Robichaud, Grant Ongo, Ivan Teahulos, Woojong Rho, Milad Dagher. Treatment-Specific Immune Phenotypes Identified by nELISA High-Throughput Proteomics Reveal Actionable Insights for Drug Discovery [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A029.
Abstract A030: Blood-based screening panel for lung cancer based on clonal hematopoietic mutations in tumor infiltrating immune cells
Authors: Anandakrishnan Ramu , Shahidi Ryan , Dai Andrew , Antony Veneeth 
Published: December 2023

Abstract
Early detection can significantly reduce mortality due to lung cancer. However, the high cost of the currently approved screening protocol has limited its uptake. Presented here is a blood-based screening panel based on clonal hematopoietic mutations. Mutations in tumor cells that inhibit immune destruction have been extensively studied. However, mutations in immune cells that may prevent an effective anti-tumor immune response remain relatively unstudied. Animal model studies suggest that clonal hematopoietic mutations in tumor infiltrating immune cells can modulate cancer progression, representing potential predictive biomarkers. The goal of this study was to determine if the clonal expansion of these mutations in blood samples could predict the occurrence of lung cancer. We identified a set of 98 potentially pathogenic clonal hematopoietic mutations in tumor infiltrating immune cells. A logistic regression machine learning model based on these mutations correctly classified lung cancer and non-cancer blood samples with 94.12% sensitivity (95% Confidence Interval: 92.20-96.04%) and 85.96% specificity (95% Confidence Interval: 82.98-88.95%) in a test set of 578 lung cancer and 545 non-cancer samples from 18 different cohorts. More importantly, 89.98% of the cancer cases were unambiguously predicted with probability of cancer &gt;0.90 and 74.86% of the non-cancer cases with probability of cancer &lt;0.10. These results suggest that it may be possible to develop an accurate blood-based lung cancer screening panel. Unlike most other “liquid biopsies” currently under development, the assay presented here is based on standard sequencing protocols and uses a relatively small number of rationally selected mutations as predictors.
Citation Format: Ramu Anandakrishnan, Ryan Shahidi, Andrew Dai, Veneeth Antony. Blood-based screening panel for lung cancer based on clonal hematopoietic mutations in tumor infiltrating immune cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A030.
Abstract A033: Secretogranin V as a Potential Biomarker for Esophageal Squamous Cell Carcinoma
Authors: Hamrah Mohammad Hussain 
Published: December 2023

Abstract
Background: Oesophageal squamous cell carcinoma (ESCC) remains one of the most poorly diagnosed and deadly cancers worldwide. Identification of biomarkers to accurately predict the risk of recurrence and survival after surgery is therefore crucial to improving patient outcomes. This study examined the expression of Secretogranin V (SCG5) and its correlation with the prognosis of patients with ESCC.
Methods: Transcription levels of SCG5 were evaluated in 22 cell lines of ESCC. The biological roles of SCG5 in cell invasion, proliferation, and migration were verified by small interfering RNA- mediated knockdown experiments. The expression of SCG5 was measured in 165 ESCC tissues by using quantitative reverse-transcription (qRT)-PCR, and its association with clinicopathological parameters was analyzed.
Results: SCG5 mRNA expression levels varied widely in ESCC cell lines. Knockdown of SCG5 expression significantly suppressed cell invasion, proliferation, and migration of ESCC cells in vitro. Analysis of clinical specimens revealed that the expression of SCG5 mRNA was overexpressed in the ESCC compared to the adjacent normal oesophageal tissues. The high SCG5 expression group had significantly shorter overall and disease-free survival times. In the multivariable analysis, the high expression of SCG5 was determined to be an independent poor prognostic factor.
Conclusion: SCG5 may have a significant role as a diagnostic and prognostic biomarker for ESCC.
Citation Format: Mohammad Hussain Hamrah. Secretogranin V as a Potential Biomarker for Esophageal Squamous Cell Carcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl):Abstract nr A033.